U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)
(Not for submission under 37 GFR 1.99)

***************************************		10531630	
		2005-04-14	
First Named Inventor Kırvin		L. Hodge	
Art Unit		1621	
Examiner Name	Deborah D. Carr		
Attorney Docket Number		18030-PCTUS	

				U.S.	PATENTS			Kemove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Pat of cited Doc	tentee or Applicant ument	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	3976673	A1	1976-08-24	Pifferi				
	2	4939171	A1	1990-07-03	Moeller, et al.				
If you wis	h to a	dd additional U.S. Pate	ent citatio	n information p	lease click the	Add button.		Add	_
			U.S.P	ATENT APPL	CATION PUB	LICATIONS		Remove	_
		Kind Code ¹	Publication Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
If you wis	1 h to a	dd additional U.S. Pub	lished Ap	plication citation	on information	please click the Ad	d button	Add	
				FOREIGN PA	TENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	1
	1	1300142	EP	A1	2003-04-09	lkawa, et al.			
	_		_		_	-	_		+

II S DATEMES

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

EP

A1 2001-05-16

3 1099701

Application Number		10531630		
Filing Date		2005-04-14		
First Named Inventor Kırvin		L. Hodge		
Art Unit		1621		
Examiner Name Debo		rah D. Carr		
Attack on Dealest North	or	19020 DCTHS		

Bertinato, et al.

	4	1995/020578	wo	A1	1995-08-03	Fenton, et al.		
	5	1994/005153	wo	A1	1994-03-17	Patel, et al.		
	6	1999/054284	wo	A1	1999-10-28	Oku, et al.		
	7	2001/060813	wo	A1	2001-08-23	Ohkubo, et al.		
	8	1593667	EP	A1	2005-11-09	Ishihara, et al.		
	9	2002/100341	wo	A2	2002-12-19	Sharma, et al.		
If you wis	h to a	d additional Foreign P				ease click the Add buttor		
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when appropriate, pages(s), volume-is		Ţŝ
	1	Jones, "Halogenation of Chemical Society, pages				Substituted Phenyl Esthers	, Journal of the	
	2	Kuchar, et al., "Synthesis of anylacetic acid and their effect on activation of fibrinolysis. Quantitative relations between structure and biological activity", Collection of Czechoslovak Chemical Communications, 45(5), pages 1401-1409, 1980. XV PO0247861.						
	-							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10531630		
Filing Date		2005-04-14		
First Named Inventor	Kırvin	L. Hodge		
Art Unit		1621		
Examiner Name	Debo	rah D. Carr		
Attomory Docket Number		19020 DCTHS		

3	Orr, et al., "Improved synthesis of 5-benzyl-2-thouracits", Synthetic Communications, 26(1), pages179-189, 1996. XP-002418933.	
4	Buu, et al., "Antinflammatory and analgesic aryleoethydroxamic acids", Chim. Ther., 2(1), pages 39-48, 1967. XIP-002418934.	
5	Kuchar, et al., 'The synthesis of anylpropionic acids and the quantitative relationship between the structure and the activation of fibrinolysis', 'Collection of Czechoslovak Chemical Communications, 46(5), pages 1173-1187, 1981. XP-002418936.	
6	Kuchar, et al., 'Relationships between gas-liquid chromatographic behavior and structure of anyl-aliphatic acid', Journal of Chromatograph, 333(1), pages 21-28, 1995. XP-002419937.	
7	Davies, et al., "Asymmetric intramolecular C-H Insertions of Arykilazoacetates", Organic Letters, 3(10), 1475-1477, 2001. XP-002418939.	
8	Coates, et al., "Opolic nucleotide phosphodiesterase inhibition by imidazopyndines: analogs of sulmazole and somazone in tribitors of the CRMP specific phosphodiesterase", Journal of Medicinal Chemistry, 36(10), 1397-1392,	
9	Maeroker, "Cleavage of cyclopropylcarbinyl phenyl ether by alkalı metala", Justus Liebigs Annalen der Chemie, 730, pages 91-99, 1969. XP-002419941.	
10	Chemical abstract DN 95:150228, also cited as ES488558, XP-002418935.	
11	Chemical abstract DN 139 214465, also cited as WO03070686, XP-002418942.	
12	Chemical abstract DN 141:71356, also cited as WO04052839. XP-002418943.	
13	Chemical abstract DN:142.279952, also cited as WO05016862 XP-002418944.	

	Application Number		10531630		
	Filing Date		2005-04-14		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	Kırvin	L. Hodge		
	Art Unit		1621		
	Examiner Name Debo		orah D. Carr		
	Attorney Docket Numb	er	18030-PCTUS		

If you wish to add add	ditional non-patent literature document citation information p	ease click the Add b	outton Add
	EXAMINER SIGNATURE		
Examiner Signature		Date Considered	
*EXAMINER: Initial if	reference considered, whether or not citation is in conforma	ance with MPEP 609	Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at sever_USPTO_GOV or MPEP 99104. I Enter office that issued the document, by the two-letter code (WIPO Standard ST3). I For Jupanese patent documents, the edication of the year of the relign of the Emperor must precede the serial number of the patent document.

Affice of coduments of the appropriate invarious as ancidated on the document under WIPO Standard ST3 if seleptions. It is placed as for serial number of the seria

English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10531630		
Filing Date		2005-04-14		
First Named Inventor	Kırvin	L. Hodge		
Art Unit		1621		
Examiner Name	Debo	rah D. Carr		
Attorney Docket Numb	ec	18030-PCTUS		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
\times	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information displacate statement. Con 27 CER 1 07(a)/1)

OR

	That no item of information contained in the information disclosure statement was cited in a communication from a
	foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
	after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
]	any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lewis J. Kreisler/	Date (YYYY-MM-DD)	2007-04-02
Name/Print	Lewis J. Kreisler	Registration Number	38522

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.